{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P1Y", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "Division of Drug Information", "hasEmail": "mailto:druginfo@fda.hhs.gov"}, "description": "Imatinib Mesylate is a generic prescription oral tablet medication that inhibits certain enzymes to treat conditions like chronic myeloid leukemia and gastrointestinal stromal tumors. Available in 100mg and 400mg strengths from Chartwell RX, LLC, it was approved under ANDA208429 and first marketed in 2019. This information was generated using AI and is provided for informational and research purposes only.", "distribution": [{"@type": "dcat:Distribution", "description": "\n        Access the FDA dataset for Imatinib mesylate \u2014 ANDA 212773 submitted by Mylan Institutional LLC\n    ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212773", "mediaType": "text/html", "title": "Imatinib mesylate"}], "identifier": "ANDA212773", "issued": "2016-09-16", "keyword": ["drug", "health-care", "medications", "pharmaceuticals", "public-health"], "landingPage": "https://www.fda.gov/drugs", "license": "https://open.fda.gov/license", "modified": "2025-03-17", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Imatinib mesylate"}